Metachronous triple primary neoplasms with primary prostate cancer, lung cancer, and colon cancer

186 Background: Cancer patients represent an at-risk population for Venous Thromboembolic Events (VTE). Our study aimed to evaluate the impact of VTE on the length and cost of hospital stay in French patients hospitalized for breast cancer (BC), colon cancer (CC), lung cancer (LC) or prostate cancer (PC). Methods: The French national hospital database (PMSI) and the disease-specific ICD-10 codes were used to identify BC, CC, LC or PC patients diagnosed in 2010 who were hospitalized with a VTE during the following two years. We selected stays during which a VTE occurred but was not the main reason of hospitalization (cancer was classified as primary/related diagnosis and VTE as significant associated diagnosis). Those stays were matched and compared to similar stays (same cancer and same reason for hospitalization) without VTE. Costs were calculated using the French official tariffs, from the perspective of the third-party payer. Results: We identified 214 stays for breast cancer during which a VTE occurred and was classified as significant associated diagnosis, 843 stays for colon cancer, 1301 for lung cancer, and 126 for prostate cancer. The comparison between those stays and similar stays without VTE showed significant increase of hospital stay duration in patients experiencing VTE. Median duration rose from 4 to 7 days in BC patients, from 8 to 16 days in CC, from 2 to 9 days in LC and from 6 to 10 days in PC. Consequently, the median expenditure per stay increased by 37% in BC patients with VTE (up to € 5,518), by 61% in CC (up to € 9,878), by 202% in LC (up to € 7,308) and by 22% in PC (up to € 6,200). Conclusions: When occurring during hospitalization, VTE made cancer management much heavier: patients faced prolonged hospital stays whereas healthcare system faced significant additional cost. Better prevention and follow-up measures could reduce this burden, and benefit both patients and hospitals. [Table: see text]

Download Full-text

Mortality of site-specific cancer in patients with schizophrenia: A systematic review and meta-analysis

10.21203/rs.2.12760/v1 ◽

2019 ◽

Author(s):

Liwei Ni ◽

Yuming Long ◽

Xuya Yuan ◽

Jianhao Xu ◽

Jialong Tao ◽

...

Keyword(s):

Prostate Cancer ◽

Lung Cancer ◽

Colon Cancer ◽

High Risk ◽

Mortality Rate ◽

Mortality Risk ◽

Meta Analysis ◽

Site Specific ◽

Risk Of Mortality ◽

Male Patients

Abstract Background: Numerous studies have reported contradicting results on the relationship between cancer mortality and schizophrenia. Our aim is to quantify the mortality rate of common site-specific cancers among patients with schizophrenia and to synthesize the available research evidence. Method: We performed a systemic search of the PubMed, EMBASE and Web of Science databases. Studies reporting the mortality rate of different cancer in patients with schizophrenia were included. A random-effects model was applied to calculate the pooled relative risks (RRs) with 95% confidence intervals (95%CIs). Results: Seven studies consisting of a total of 1,162,971 participants with schizophrenia were included in this meta-analysis. Data regarding mortality risk of breast, colon, lung and prostate cancer among schizophrenia patients were subjected to quantitative analysis. Pooled results showed significant increases in mortality risk of breast cancer (RR = 1.97, 95%CI 1.38–2.83), lung cancer (RR = 1.93, 95%CI 1.46–2.54) and colon cancer (RR = 1.69, 95%CI 1.60–1.80) in patients with schizophrenia compared with those in the general population or control group. The mortality risk of prostate cancer increased in male patients, although no significant difference was detected (RR = 1.58, 95% CI 0.79–3.15). Increased risks of mortality from lung and colon cancer were observed in female patients (RR = 2.49, 95%CI 2.40–2.59 and RR = 2.42, 95%CI 1.39–4.22, respectively) and elevated risks of mortality from lung and colon cancer in male patients (RR = 2.40, 95%CI 2.30–2.50 and RR = 1.90, 95%CI 1.71–2.11, respectively) were detected. Conclusions: Individuals with schizophrenia have a significantly high risk of mortality from breast, colon, and lung cancer and a high risk of mortality from prostate cancer.

Download Full-text

Community Cancer Rates in Massachusetts, New Hampshire, and Rhode Island: Findings From Healthy Aging Data Reports

Innovation in Aging ◽

10.1093/geroni/igaa057.358 ◽

2020 ◽

Vol 4 (Supplement_1) ◽

pp. 108-109

Author(s):

Shuangshuang Wang ◽

Chae Man Lee ◽

Bon Kim ◽

Nina Silverstein ◽

Frank Porell ◽

...

Keyword(s):

Breast Cancer ◽

Prostate Cancer ◽

Lung Cancer ◽

Colon Cancer ◽

Rhode Island ◽

Healthy Aging ◽

Local Community ◽

Medicare Beneficiary ◽

Later Life ◽

Cancer Rates

Abstract Cancer is one major health condition that affect people’s later life quality, which could be intervened from the community level. This study compares rates of lung cancer, colon cancer, breast cancer (in women), and prostate cancer (in men) among adults 65+ in 3 New England states (MA, NH, and RI). Data were from the Healthy Aging Data Report (see www.healthyagingdatareports.org), which reported on 150+ health indicators at the local community and state level. Data sources were the Current Medicare Beneficiary Summary File (years) and the American Community Survey (years). Small area estimation techniques were used to calculate age-sex adjusted community rates. Average state rates of cancers (range) are: Lung cancer MA 2.1 (1.0 – 4.4) NH 1.6 (0.9 – 2.9) RI 2.1 (1.3 – 2.9); Colon cancer MA 2.9 (1.8 – 4.1) NH 2.4 (1.8 – 3.7) RI 3.2 (1.6 – 4.5); Breast cancer MA 10.9 (5.3 – 16.4) NH 9.8 (5.4 – 14.8) RI 10.7 (7.2 – 13.9); Prostate cancer MA 13.8 (7.4 – 24.0) NH 11.5 (5.9 – 17.3) RI 13.8 (9.5 – 17.7). NH has the lowest rates on all four types of cancer; MA and NH were similar regarding average rates, but MA communities had the widest disparities for lung, breast and prostate cancer. Findings suggest within and between state variations in cancer rates. Policies and programs may target geographic areas/communities with high rates of cancers, examine environmental effects on cancer rates and develop strategies in reducing cancer rates.

Download Full-text

Thrombosis in Cancer Patients during Hospitalization: Impact on Stays and Costs

Blood ◽

10.1182/blood.v126.23.4487.4487 ◽

2015 ◽

Vol 126 (23) ◽

pp. 4487-4487

Author(s):

Isabelle Borget ◽

Florian Scotte ◽

Nicolas Martelli ◽

Alexandre Vainchtock ◽

Ismail Elalamy

Keyword(s):

Breast Cancer ◽

Prostate Cancer ◽

Lung Cancer ◽

Colon Cancer ◽

Hospital Stay ◽

Cancer Patients ◽

Public Hospitals ◽

Recurrent Event ◽

Additional Costs

Abstract Background: Cancer patients represent an at-risk population for Venous Thromboembolic Events (VTE). Following a previous study on two localizations, we intended to determine the incidence and recurrence rate of VTE in breast cancer (BC), colon cancer (CC), lung cancer (LC) and prostate cancer (PC), four of the most frequent cancers in France. We evaluate their impact on the number and the duration of hospitalizations and calculate the additional costs for hospitals compared to cancer patients without VTE. Methods: The French national hospital database (PMSI) was used to identify BC, CC, LC and PC patients diagnosed in 2010 who were hospitalized for a VTE during the following two years. The number of stays induced by a VTE, the number of patients hospitalized or re-hospitalized and the time before recurrent event were determined using the disease-specific ICD-10 codes, among all VTEs classified as primary or related diagnosis (PD / RD) and significant associated diagnosis (SAD). Subsequently, we evaluated the extra cost and extra duration of stay when a VTE is managed during a hospitalization. Therefore, we selected stays during witch a VTE is managed but was not the main reason of hospitalization (cancer was classified as primary/related diagnosis and VTE as significant associated diagnosis). Those stays were matched and compared to similar stays without VTE. Costs were estimated from the healthcare system perspective, using the French official tariffs. Results: Among 194,964 patients newly diagnosed in 2010 with BC, CC, LC and PC in 2010, 1,271 (2.0%) BC patients, 2,866 (6.0%) CC patients, 3,775 (9,6%) LC patients and 997 (2.2%) PC patients, were hospitalized for a VTE or experienced a VTE during a hospital stay, over two years. In total, 12,880 stays related to VTE were identified. We found that 2.053 cancer patients (23.0% of all VTE patients) were re-hospitalized at least once with a recurrent VTE, representing 3,969 admissions (30.8% of total admissions). In those patients with VTE recurrence, median time between first and recurrent event was 23 days in BC patients, 22 days in CC patients, 19 days in LC patients 25 days in PC patients. In the second part of our study, the comparison between stays for cancer during which a VTE occurred and stays for cancer without VTE showed that the duration of hospital stay was longer in patients with VTE: in public hospitals, median stay duration raised from 4 to 7 days for BC, from 8 to 16 days in CC, from 2 to 9 days in LC and from 6 to 10 days in PC. VTE consequently induced a significant extra cost related to hospitalizations over the two years of follow-up: in public hospitals, the median expenditure per stay increased by 37% in BC, (up to Û 5,518), by 61% in CC (up to Û9,878), by 202% in LC (up to Û7,308) and by 22% in PC (up to Û6,200). Conclusion: VTE appeared to make cancer management much heavier as patients faced increased hospital stays duration whereas healthcare system faced important additional costs. Better prevention and follow-up guidelines could reduce this burden, and benefit both patients and hospitals. Table. Median hospital stay duration and cost in cancer patients with and without VTE as SAD Breast cancer Colon cancer Lung cancer Prostate cancer Duration (days) Cost Duration (days) Cost Duration (days) Cost Duration (days) Cost With VTE 7 Û 5,518 16 Û9,878 9 Û7,308 10 Û 6,200 Without VTE 4 Û 4,018 8 Û6,171 2 Û2,422 6 Û 5,094 Disclosures No relevant conflicts of interest to declare.

Download Full-text

Oncology Questions and Answers

Mayo Clinic Internal Medicine Board Review Questions and Answers ◽

10.1093/med/9780199985876.003.0008 ◽

2013 ◽

pp. 79-82

Author(s):

Robert D. Ficalora

Keyword(s):

Breast Cancer ◽

Prostate Cancer ◽

Lung Cancer ◽

Ovarian Cancer ◽

Colon Cancer ◽

Multiple Choice ◽

Cancer Breast ◽

Questions And Answers ◽

Board Review ◽

Cancer Côlon

Chapter 8 presents multiple-choice, board review questions on oncology including lung cancer, colon cancer, ovarian cancer, breast cancer, and prostate cancer. Full explanations are provided with the correct answers.

Download Full-text

Mortality of site-specific cancer in patients with schizophrenia: a systematic review and meta-analysis

BMC Psychiatry ◽

10.1186/s12888-019-2332-z ◽

2019 ◽

Vol 19 (1) ◽

Cited By ~ 2

Author(s):

Liwei Ni ◽

Jian Wu ◽

Yuming Long ◽

Jialong Tao ◽

Jianhao Xu ◽

...

Keyword(s):

Prostate Cancer ◽

Lung Cancer ◽

Colon Cancer ◽

Mortality Rate ◽

Mortality Risk ◽

Meta Analysis ◽

Control Group ◽

Site Specific ◽

Significant Difference ◽

Male Patients

Abstract Background Numerous studies have reported contradicting results on the relationship between cancer mortality and schizophrenia. Our aim is to quantify the mortality rate of common site-specific cancers among patients with schizophrenia and to synthesize the available research evidence. Methods We performed a systemic search of the PubMed, EMBASE and Web of Science databases. Studies reporting the mortality rate of different cancer in patients with schizophrenia were included. A random-effects model was applied to calculate the pooled relative risks (RRs) with 95% confidence intervals (95%CIs). Results Seven studies consisting of 1,162,971 participants with schizophrenia were included in this meta-analysis. Data regarding mortality risk of breast, colon, lung and prostate cancer among schizophrenia patients were subjected to quantitative analysis. Pooled results showed significant increases in mortality risk of breast cancer (RR = 1.97, 95%CI 1.38–2.83), lung cancer (RR = 1.93, 95%CI 1.46–2.54) and colon cancer (RR = 1.69, 95%CI 1.60–1.80) in patients with schizophrenia compared with those in the general population or control group. The mortality risk of prostate cancer increased in male patients, although no significant difference was detected (RR = 1.58, 95% CI 0.79–3.15). Increased risks of mortality from lung and colon cancer were observed in female patients (RR = 2.49, 95%CI 2.40–2.59 and RR = 2.42, 95%CI 1.39–4.22, respectively) and elevated risks of mortality from lung and colon cancer in male patients (RR = 2.40, 95%CI 2.30–2.50 and RR = 1.90, 95%CI 1.71–2.11, respectively) were detected. Conclusions Individuals with schizophrenia have a significantly high risk of mortality from breast, colon, and lung cancer.

Download Full-text

Chromene, Quinoline Hybrids as Potential Anti-Cancer Agents: A Novel and Distinct Approach for the Synthesis of Quinoline Derivatives..

Letters in Organic Chemistry ◽

10.2174/1570178617666200122095829 ◽

2020 ◽

Vol 17 ◽

Author(s):

Rizuana Sultana ◽

Ravinder Reddy Tippanna

Keyword(s):

Prostate Cancer ◽

Lung Cancer ◽

Colon Cancer ◽

Cancer Cells ◽

Annexin V ◽

Lung Cancer Cells ◽

Quinoline Derivatives ◽

Prostate Cancer Cells ◽

Diverse Range ◽

Anti Cancer

: A series of novel quinoline derivatives (6-phenyl-6H-chromeno[4,3-b]quinoline) have been prepared by using 4-chloro-2-phenyl-2H-chromene-3-carbaldehyde and various substituted isocyanides as starting materials in the presence of HClO4-SiO2 and Methanol. We screened eighteen compounds of this novel series (6a-r) in six different cancer cell lines (A549 (lung cancer cells), DU145 (prostate cancer cells), PC3 (prostate cancer cells), MCF7 (lung cancer cells), HT 29, HCT 116 (colon cancer cells)). Most of the compounds showed anti-cancer activity and compound 6b showed good cytotoxicity IC50 = 2.61±0.34 µM against colon cancer on HT29 cell line among all. The key property of cell migration was observed while treatment cells with 6b. Apoptosis in HT29 cells confirmed by annexin V staining, acridine orange/ethidium bromide (AO/EB), DAPI, induced by 6b. This method is operationally simple and works with a diverse range of substrates. These results indicate the anticancer potential of these series and warrants future investigations for further anticancer drug development.

Download Full-text